Soyama N, Ohyanagi H, Saitoh Y
First Department of Surgery, Kobe University School of Medicine.
Nihon Shokakibyo Gakkai Zasshi. 1990 Dec;87(12):2635-41.
Lymphocytes obtained from regional lymph nodes and spleen in the patients with gastrointestinal carcinoma were fused with the human B lymphoblastoid cell line GC01 and human hybridomas producing human monoclonal antibody (MoAb) were derived. Human MoAb No. 235 (IgM) derived from spleen cell of a gastric cancer patient reacted with adenocarcinoma of stomach, colon, and pancreas in the new immunohistochemical assay, modified direct immunoperoxidase method, and reacted with KATO III cells in cultured cell lines. The antigenic determinant of this antibody was suspected to be protein moiety after enzyme treatment. The competitive binding inhibition assay indicated that its epitope was different from anti-CEA monoclonal antibodies (KM10, A10, B9, AH3, JA4) and KM01. These findings suggested the possible use of human MoAb No. 235 for clinical application of targeting cancer chemotherapy in the future.
从胃肠道癌患者的区域淋巴结和脾脏中获取淋巴细胞，将其与人类B淋巴母细胞系GC01融合，从而获得产生人单克隆抗体（MoAb）的人杂交瘤。源自一名胃癌患者脾细胞的人MoAb No. 235（IgM），在新的免疫组织化学检测方法（改良直接免疫过氧化物酶法）中，与胃癌、结肠癌和胰腺癌发生反应，并且与培养细胞系中的KATO III细胞发生反应。经酶处理后，怀疑该抗体的抗原决定簇为蛋白质部分。竞争性结合抑制试验表明，其表位不同于抗CEA单克隆抗体（KM10、A10、B9、AH3、JA4）和KM01。这些发现提示人MoAb No. 235未来可能用于癌症靶向化疗的临床应用。
